Gaxos.ai Inc. - GXAI STOCK NEWS

Gaxos.ai, an artificial intelligence applications developer, has announced its participation in two major gaming conferences in Cologne, Germany. The company will attend the Devcom Developer Conference from August 18th to 20th and the Gamescom Conference from August 21st to 25th, 2024.

CEO Vadim Mats expressed enthusiasm about the opportunity to engage with developers, industry leaders, and gamers. Gaxos aims to establish meaningful connections and grow its AI product for game developers and publishers. Interested parties can arrange meetings or press inquiries by emailing press@gaxos.ai.

Gaxos.ai has announced the commercial launch of Gaxos Health, marking its transition from development to revenue generation. The company recorded its initial revenue this week, signaling a significant milestone. Gaxos Health aims to optimize human performance through personalized health and wellness plans using science and technology.

The offering includes biomarker testing, customized nutrition plans, fitness routines, supplement plans, and live coaching. CEO Vadim Mats expressed enthusiasm about the launch, emphasizing the company's goal to become a leader in the personalized health services industry. Gaxos Health plans to expand its services with AI-enabled applications and additional health and wellness offerings.

Gaxos.ai (GXAI) has announced strategic partnerships with leading testing laboratories for its Gaxos Health division. This move is a significant step towards the commercial launch of their personalized health and wellness solutions. CEO Vadim Mats expressed excitement about the partnerships, highlighting their potential to transform the health and wellness experience for clients.

These collaborations are important for Gaxos Health's mission to optimize human performance through customized health plans and coaching, leveraging science and technology. The partnerships are expected to enhance Gaxos' ability to deliver impactful, personalized results to its clients, marking a pivotal milestone in the company's development.

On July 10, 2024, Gaxos.AI, a firm specializing in AI applications, announced a partnership with Meshy to integrate AI-generated 3D models into its solutions for game developers and publishers. This collaboration aims to deliver high-quality 3D assets, enhancing the toolkit available to game developers. Vadim Mats, CEO of Gaxos.AI, expressed enthusiasm about the partnership's potential to make their product an essential resource for the gaming industry. Ethan Hu, CEO of Meshy, highlighted the opportunity to provide innovative tools that simplify the creation of detailed and immersive 3D models for users.

Gaxos.AI has announced the successful completion of its AI solution development for game developers and publishers. The solution aims to enhance revenue opportunities and expedite game development processes. The AI product is currently in closed beta, being tested by independent developers. Key features include AI-powered creativity, reducing asset development time from hours to minutes, seamless integration with Unity and upcoming support for Unreal Engine, dynamic content generation through User-Generated-AI-Content (UGAiC), and customized solutions with tailored AI models and consulting services. The company aims to leverage this advancement to deliver shareholder value.

Gaxos Health, a subsidiary of Gaxos.ai Inc., has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell. Dr. Margolis brings over 25 years of experience in urology, focusing on men's health and regenerative therapies. Dr. Pavell specializes in physical medicine and rehabilitation, offering advanced non-operative treatments. The addition of these top medical talents demonstrates Gaxos Health's commitment to providing innovative solutions and creating value for shareholders.

Gaxos.ai Inc. (NASDAQ: GXAI) has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. The Company's common stock traded above $1.00 for 10 consecutive days as of March 21, 2024, resolving the non-compliance issue.

Gaxos.ai Inc. (GXAI) closed a private placement offering, selling 628,367 shares of common stock, series A warrants, and short-term series B warrants at $5.57 per share. The gross proceeds were $3.5 million. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.

Gaxos.ai Inc. (NASDAQ: GXAI) announced a private placement of common stock and warrants, totaling 628,367 shares, at a purchase price of $5.57 per share. The series A and short-term series B warrants have exercise prices of $5.50 per share and expire at different intervals. The private placement is set to close soon.